INT34488

Context Info Confidence 0.59 First Reported 1987 Last Reported 2010 Negated 1 Speculated 0 Reported most in Abstract Documents 85 Total Number 90 Disease Relevance 41.98 Pain Relevance 21.72

peptidase activity (MMP2) extracellular space (MMP2) extracellular region (MMP2) proteinaceous extracellular matrix (MMP2) plasma membrane (MMP2) nucleus (MMP2)

Anatomy Link Frequency cartilage 3 lung 3 joints 2 1A2 2 extracellular matrix 2 MMP2 (Homo sapiens)

Pain Link Frequency Relevance Heat metalloproteinase 2167 100.00 ischemia 25 100.00 COX-2 inhibitor 144 99.98 cytokine 483 99.88 Cannabinoid 78 99.82 Inflammation 473 99.70 cINOD 64 99.58 Calcitonin gene-related peptide 44 99.48 Arthritis 233 99.20 Potency 39 99.16

Disease Link Frequency Relevance Heat Metastasis 299 100.00 Cv Unclassified Under Development 19 100.00 Primary Sclerosing Cholangitis 132 99.90 Pancreatic Cancer 91 99.84 Glioblastoma 24 99.78 Carcinoma 26 99.74 INFLAMMATION 552 99.70 Major Depressive Disorder 25 99.56 Lung Cancer 29 99.52 Arthritis 306 99.48

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Their functional effects, including the inhibition of MMP2, were shown to be involved VEGF-triggered ERK1/2 pathways.

Negative_regulation (inhibition) of MMP2

1) Confidence 0.59 Published 2009 Journal Oncol. Res. Section Abstract Doc Link 19806782 Disease Relevance 0.06 Pain Relevance 0.11

RESULTS: ZnSO4 was a strong inhibitor of MMP-2 (I50 = 15 microM) and MMP-9 (I50 = 40 microM), whereas CuSO4, HgSO4 and SnCl2 showed less efficient inhibition potential.

Negative_regulation (inhibitor) of MMP-2

2) Confidence 0.58 Published 2000 Journal Dent Mater Section Body Doc Link 11203530 Disease Relevance 0 Pain Relevance 0

Inhibition of human gingival gelatinases (MMP-2 and MMP-9) by metal salts.

Negative_regulation (Inhibition) of MMP-2

3) Confidence 0.58 Published 2000 Journal Dent Mater Section Title Doc Link 11203530 Disease Relevance 0.27 Pain Relevance 0.22

It also lowered down the activity of MMP-2 and MMP-9, and could reduce of MMP-2 secretion of cell lines.

Negative_regulation (lowered) of MMP-2

4) Confidence 0.57 Published 2005 Journal J. Neurooncol. Section Abstract Doc Link 15803368 Disease Relevance 0.26 Pain Relevance 0

The proteolytic activities of MMP-2 and MMP-9 were strongly inhibited by dispersed phase amalgams conditioned buffers.

Negative_regulation (inhibited) of MMP-2

5) Confidence 0.57 Published 2001 Journal Biomaterials Section Abstract Doc Link 11426881 Disease Relevance 0.24 Pain Relevance 0.23

Inhibition of MMP-2 and MMP-9 activities was partly prevented by the addition of 1,10 phenanthroline, a divalent metal chelator, to the amalgam conditioned buffers.

Negative_regulation (Inhibition) of MMP-2

6) Confidence 0.57 Published 2001 Journal Biomaterials Section Abstract Doc Link 11426881 Disease Relevance 0.23 Pain Relevance 0.23

(b) MMP-2 activity that changed from pro-MMP-2 to active form of MMP-2 in supernatants of cell lines could not be inhibited by indomethacin.

Negative_regulation (inhibited) of MMP-2

7) Confidence 0.50 Published 2005 Journal J. Neurooncol. Section Abstract Doc Link 15803368 Disease Relevance 0.41 Pain Relevance 0.18

Since MMPs involve in joint inflammation, it can be presumed that inhibition of MMP-2 and MMP-9 can be one of the mechanisms of SGlc to be an effective drug in relieving the symptoms of osteoarthritis.

Negative_regulation (inhibition) of MMP-2 in joint associated with inflammation, osteoarthritis and arthritis

8) Confidence 0.48 Published 2007 Journal Bioorg. Med. Chem. Section Abstract Doc Link 17498959 Disease Relevance 0.52 Pain Relevance 0.22

Further, transfection of promoter genes of MMPs and their transcription factors clearly exhibited that inhibition of MMP-2 and MMP-9 was due to down-regulation of transcription factor, NF-kappaB.

Negative_regulation (inhibition) of MMP-2

9) Confidence 0.48 Published 2007 Journal Bioorg. Med. Chem. Section Abstract Doc Link 17498959 Disease Relevance 0.48 Pain Relevance 0.20

Selective inhibition of endogenous MMP-2 with the novel tissue-permeable cyclic peptide CTTHWGFTLC (CTT, 10 micromol/L) also caused vasorelaxation (by 85+/-6%), whereas STTHWGFTLS (10 micromol/L), an inactive CTT analogue, did not dilate the arteries.

Negative_regulation (inhibition) of MMP-2 associated with metalloproteinase

10) Confidence 0.45 Published 2000 Journal Circ. Res. Section Abstract Doc Link 11029402 Disease Relevance 0.07 Pain Relevance 0.62

In this respect, polyphenols of blackberry fruit (21) and green tea (22), reportedly inhibit hyaluronidase and gelatinase activities, respectively.

Negative_regulation (inhibit) of gelatinase

11) Confidence 0.43 Published 2008 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2529383 Disease Relevance 0.50 Pain Relevance 0.17

Taking into consideration that TIMP-2 functions predominantly as an MMP9 inhibitor (through its catalytic domain) and a proMMP2 activator (through its noncatalytic haemopexin domain), the presence of anti-TIMP-2 antibodies may favour accumulation of functional MMP2.

Negative_regulation (inhibitor) of MMP2

12) Confidence 0.42 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1257425 Disease Relevance 0.56 Pain Relevance 0.31

It also lowered down the activity of MMP-2 and MMP-9, and could reduce of MMP-2 secretion of cell lines.

Negative_regulation (reduce) of MMP-2

13) Confidence 0.42 Published 2005 Journal J. Neurooncol. Section Abstract Doc Link 15803368 Disease Relevance 0.26 Pain Relevance 0

MMP-2, -3, and IL-8 mRNA expression was up-regulated by the compression, and both MMP-1 and -3 protein expression and MMP-2 activity were detected.

Negative_regulation (detected) of MMP-2

14) Confidence 0.41 Published 2007 Journal J. Dent. Res. Section Abstract Doc Link 17652211 Disease Relevance 0.99 Pain Relevance 0.71

Additionally, this COX-2 inhibitor attenuated the degrading activity of MMP-2 as demonstrated by gelatin zymography.

Negative_regulation (attenuated) of MMP-2 associated with cox-2 inhibitor

15) Confidence 0.41 Published 2001 Journal FEBS Lett. Section Abstract Doc Link 11728453 Disease Relevance 0.40 Pain Relevance 0.29

The use of an ELISA and zymography demonstrated that MMP-2 and MMP-9 enzyme activity were decreased in HT-29 cells by treatment with various concentration of 5-aminosalicylic acid.

Negative_regulation (decreased) of MMP-2 in HT-29

16) Confidence 0.40 Published 2009 Journal Dig Liver Dis Section Body Doc Link 18976971 Disease Relevance 0.14 Pain Relevance 0

Activated MMP1, MMP3 and latent forms of MMP2 and MMP9 are regulated and inhibited by endogenous proteins known as tissue inhibitors of metalloproteinase TIMP1 and TIMP2 [17].

Negative_regulation (inhibited) of MMP2 associated with metalloproteinase

17) Confidence 0.40 Published 2006 Journal BMC Urol Section Body Doc Link PMC1560390 Disease Relevance 0.83 Pain Relevance 0.23

Inhibition of MMP-2 increased the amount of intact CGRP in arteries and enhanced vasorelaxation induced by anandamide, which stimulates CGRP release.

Negative_regulation (Inhibition) of MMP-2 associated with metalloproteinase and calcitonin gene-related peptide

18) Confidence 0.39 Published 2000 Journal Circ. Res. Section Abstract Doc Link 11029402 Disease Relevance 0.14 Pain Relevance 1.13

Interestingly, the vasorelaxation that results from MMP-2 inhibition was endothelium-independent.

Negative_regulation (inhibition) of MMP-2 in endothelium associated with metalloproteinase

19) Confidence 0.39 Published 2000 Journal Circ. Res. Section Abstract Doc Link 11029402 Disease Relevance 0.07 Pain Relevance 0.91

The mechanism of significant inhibition of HT1080 cells invasion by fucoidan extracts, possibly via suppressing MMP-2 and MMP-9 activities.

Negative_regulation (suppressing) of MMP-2

20) Confidence 0.38 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707034 Disease Relevance 0.40 Pain Relevance 0.14

General Comments

This test has worked.